Fig. 4From: Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosisDuration of simulated % Emax for sCTX inhibition over 24 h evaluated for the following categories of % Emax: ≥90, ≥70, ≥50 and ≥30%Back to article page